TY - JOUR
T1 - A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides
AU - Albert, Daniel M.
AU - Gangnon, Ronald E.
AU - Grossniklaus, Hans E.
AU - Green, W. Richard
AU - Darjatmoko, Soesiawati
AU - Kulkarni, Amol D.
PY - 2008/5
Y1 - 2008/5
N2 - Objectives: To study the histopathological features of latanoprost-treated irides with or without darkening, compared with non-latanoprost-treated irides. Methods: Iridectomy specimens and patient history forms were independently examined by 3 ophthalmic pathologists in a masked fashion. Specimens were evaluated for premalignant changes and for differences in level of pigmentation and degrees of cellularity, inflammation, and vascular abnormalities. Results: The specimens consisted of 22 latanoprost-treated darkened irides, 35 latanoprost-treated irides without darkening, and 35 non-latanoprost-treated irides. There was a statistically significant decrease in the number of nuclear invaginations and prominent nucleoli in latanoprost-treated darkened irides compared with the other 2 groups (P = .004 and P = .005, respectively). The average thickness and pigmentation of the anterior border layer was greater in the latanoprost-treated darkened irides than in the other 2 groups (P = .03 and P = .02, respectively). The latanoprost-treated darkened irides had increased pigmentation of the stroma (P < .001), stromal fibroblasts (P < .001), melanocytes (P = .005), vascular endothelium (P = .02), and adventitia (P < .001) relative to the other 2 groups. Conclusions: There is no histopathological evidence of premalignant changes in latanoprost-treated darkened irides. The latanoprost-induced iris color changes are due to a thickening of the anterior border layer and an increased amount of melanin in the anterior border layer and within the stromal melanocytes.
AB - Objectives: To study the histopathological features of latanoprost-treated irides with or without darkening, compared with non-latanoprost-treated irides. Methods: Iridectomy specimens and patient history forms were independently examined by 3 ophthalmic pathologists in a masked fashion. Specimens were evaluated for premalignant changes and for differences in level of pigmentation and degrees of cellularity, inflammation, and vascular abnormalities. Results: The specimens consisted of 22 latanoprost-treated darkened irides, 35 latanoprost-treated irides without darkening, and 35 non-latanoprost-treated irides. There was a statistically significant decrease in the number of nuclear invaginations and prominent nucleoli in latanoprost-treated darkened irides compared with the other 2 groups (P = .004 and P = .005, respectively). The average thickness and pigmentation of the anterior border layer was greater in the latanoprost-treated darkened irides than in the other 2 groups (P = .03 and P = .02, respectively). The latanoprost-treated darkened irides had increased pigmentation of the stroma (P < .001), stromal fibroblasts (P < .001), melanocytes (P = .005), vascular endothelium (P = .02), and adventitia (P < .001) relative to the other 2 groups. Conclusions: There is no histopathological evidence of premalignant changes in latanoprost-treated darkened irides. The latanoprost-induced iris color changes are due to a thickening of the anterior border layer and an increased amount of melanin in the anterior border layer and within the stromal melanocytes.
UR - http://www.scopus.com/inward/record.url?scp=43549086687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43549086687&partnerID=8YFLogxK
U2 - 10.1001/archopht.126.5.626
DO - 10.1001/archopht.126.5.626
M3 - Article
C2 - 18474771
AN - SCOPUS:43549086687
SN - 2168-6165
VL - 126
SP - 626
EP - 631
JO - JAMA Ophthalmology
JF - JAMA Ophthalmology
IS - 5
ER -